This patent covers mesenchymal stem cells that are treated with interferon gamma for suppression of an immune response. Mesenchymal stem cells are naturally immunosuppressive...it may be that the interferon gamma treatment is activating the expression of the immune suppressive enzyme 2,3-indolamine-dehydrogenase (IDO), which selectively depletes tryptophan, thus stopping T cell activation.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.